Kieran Feltham

Kieran is a MRes graduate who has previously worked in a COVID laboratory. He has joined the Fibrosis team to perform High Throughput Screenings to find drugs for the prevention of fibrosis.

[email protected]

Background

Kieran obtained his BSc Biochemistry and more recently his MRes Cancer Biology degree at Nottingham Trent University in 2021, where his project investigated the role of a long non-coding NA in DNA damage and cell survival. At the start of 2022 he was performing COVID and variant detection using NGS, until he began his job at ARU in August 2022 with the fibrosis team.

The team has recently completed their phenotypic screening of AstraZenecas annotated compound library using a hypertrophic scar assay, and Kieran has now started development of a clinically relevant 3D model of fibrosis to use for future phenotypic screening assays.

Previous projects:

• Development of a 384-well high throughput phenotypic screening assay for hypertrophic scars.
• Screening of AstraZenecas annotated compound library for hypertrophic scars.

Current project:

• Development of a clinically relevant 3D model of fibrosis.

Research interests

• Fibrosis and fibroproliferative disorders
• Phenotypic drug discovery and assay development
• High throughput screening optimisation

Qualifications

• Diploma of Professional Practice, Nottingham Trent University (2018)
• BSc (Hons) Biochemistry, Nottingham Trent University (2019)
• MRes Cancer Biology, Nottingham Trent University (2021)

Selected recent publications

Lapthorn AR, Harding SL, Feltham KM, Sathyananth D, Salisbury DC, Cellek S. A Review of the Current Landscape of Anti-Fibrotic Medicines. Fibrosis. 2024; 2(3):10005. https://doi.org/10.70322/fibrosis.2024.10005

Recent presentations and conferences

Feltham, KM. Adaptation of a phenotypic screening assay to incorporate 384-well plates: Opening the door to high throughput screening. The British Society for Investigative Dermatology Annual Meeting (April 2024, Southampton, UK).